Expert Interview
A second look: Discussing the top-line results from Amgen and Kyowa Kirin's Rocatinlimab Phase 3 IGNITE study in adults with moderate to severe atopic dermatitis
Ticker(s): AMGN, KY4.XFRAInstitution: Private Practice
- Board-Certified dermatologist practicing cosmetic, medical, surgical and pediatric dermatology.
- Manages around 800 atopic dermatitis patients a year.
- Very familiar with the ox-40 data.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
